BACKGROUND: SRC activation is associated with cell migration, proliferation, and metastasis. Saracatinib is an oral tyrosine kinase inhibitor (TKI) selective for SRC. We performed this trial to evaluate the efficacy and safety of saracatinib monotherapy in patients with estrogen receptor (ER)(-) and progesterone receptor (PR)(-) metastatic breast cancer (MBC). PATIENTS AND METHODS: Patients who had undergone ≤ 1 previous chemotherapy regimen for measurable ER(-) and PR(-) MBC received saracatinib 175 mg orally daily. The primary endpoint was disease control defined as complete response (CR) + partial response (PR) + stable disease (SD) > 6 months. Secondary endpoints included toxicity and progression-free survival (PFS). Levels of circulating tumor cells (CTCs) in response to therapy were measured over time. RESULTS: Nine patients were treated on study. After a median of 2 cycles (range 1-3), no patient had achieved CR, PR, or SD >6 months. The median time to treatment failure was 82 days (12-109 days).The majority (89%) of patients discontinued saracatinib because of disease progression. One patient acquired potentially treatment-related grade 4 hypoxia with interstitial infiltrates and was removed from the study. Common adverse events included fatigue, elevated liver enzymes, nausea, hyponatremia, dyspnea, cough, and adrenal insufficiency. CONCLUSIONS: These efficacy results were not sufficiently promising to justify continued accrual to this study. Based on this series, saracatinib does not appear to have significant single-agent activity for the treatment of patients with ER(-)/PR(-) MBC.
BACKGROUND:SRC activation is associated with cell migration, proliferation, and metastasis. Saracatinib is an oral tyrosine kinase inhibitor (TKI) selective for SRC. We performed this trial to evaluate the efficacy and safety of saracatinib monotherapy in patients with estrogen receptor (ER)(-) and progesterone receptor (PR)(-) metastatic breast cancer (MBC). PATIENTS AND METHODS: Patients who had undergone ≤ 1 previous chemotherapy regimen for measurable ER(-) and PR(-) MBC received saracatinib 175 mg orally daily. The primary endpoint was disease control defined as complete response (CR) + partial response (PR) + stable disease (SD) > 6 months. Secondary endpoints included toxicity and progression-free survival (PFS). Levels of circulating tumor cells (CTCs) in response to therapy were measured over time. RESULTS: Nine patients were treated on study. After a median of 2 cycles (range 1-3), no patient had achieved CR, PR, or SD >6 months. The median time to treatment failure was 82 days (12-109 days).The majority (89%) of patients discontinued saracatinib because of disease progression. One patient acquired potentially treatment-related grade 4 hypoxia with interstitial infiltrates and was removed from the study. Common adverse events included fatigue, elevated liver enzymes, nausea, hyponatremia, dyspnea, cough, and adrenal insufficiency. CONCLUSIONS: These efficacy results were not sufficiently promising to justify continued accrual to this study. Based on this series, saracatinib does not appear to have significant single-agent activity for the treatment of patients with ER(-)/PR(-) MBC.
Authors: Matthew H Herynk; Amanda R Beyer; Yukun Cui; Heidi Weiss; Elizabeth Anderson; Tim P Green; Suzanne A W Fuqua Journal: Mol Cancer Ther Date: 2006-12 Impact factor: 6.261
Authors: Heike Aligayer; Douglas D Boyd; Markus M Heiss; Eddie K Abdalla; Steven A Curley; Gary E Gallick Journal: Cancer Date: 2002-01-15 Impact factor: 6.860
Authors: Moshe Talpaz; Neil P Shah; Hagop Kantarjian; Nicholas Donato; John Nicoll; Ron Paquette; Jorge Cortes; Susan O'Brien; Claude Nicaise; Eric Bleickardt; M Anne Blackwood-Chirchir; Vishwanath Iyer; Tai-Tsang Chen; Fei Huang; Arthur P Decillis; Charles L Sawyers Journal: N Engl J Med Date: 2006-06-15 Impact factor: 91.245
Authors: Stephen Hiscox; Liam Morgan; Tim P Green; Denise Barrow; Julia Gee; Robert I Nicholson Journal: Breast Cancer Res Treat Date: 2005-12-07 Impact factor: 4.872
Authors: Stephen Hiscox; Liam Morgan; Denise Barrow; Carol Dutkowskil; Alan Wakeling; Robert I Nicholson Journal: Clin Exp Metastasis Date: 2004 Impact factor: 5.150
Authors: Massimo Cristofanilli; G Thomas Budd; Matthew J Ellis; Alison Stopeck; Jeri Matera; M Craig Miller; James M Reuben; Gerald V Doyle; W Jeffrey Allard; Leon W M M Terstappen; Daniel F Hayes Journal: N Engl J Med Date: 2004-08-19 Impact factor: 91.245
Authors: Tim P Green; Mike Fennell; Robin Whittaker; Jon Curwen; Vivien Jacobs; Jack Allen; Armelle Logie; Judith Hargreaves; D Mark Hickinson; Robert W Wilkinson; Paul Elvin; Brigitte Boyer; Neil Carragher; Patrick A Plé; Alun Bermingham; Geoffrey A Holdgate; Walter H J Ward; Laurent F Hennequin; Barry R Davies; Gerard F Costello Journal: Mol Oncol Date: 2009-02-07 Impact factor: 6.603
Authors: T Masaki; K Igarashi; M Tokuda; S Yukimasa; F Han; Y J Jin; J Q Li; H Yoneyama; N Uchida; J Fujita; H Yoshiji; S Watanabe; K Kurokohchi; S Kuriyama Journal: Eur J Cancer Date: 2003-07 Impact factor: 9.162
Authors: Jon R Wiener; T Christopher Windham; Veronica C Estrella; Nila U Parikh; Peter F Thall; Michael T Deavers; Robert C Bast; Gordon B Mills; Gary E Gallick Journal: Gynecol Oncol Date: 2003-01 Impact factor: 5.482
Authors: Lara H El Touny; Anthony Vieira; Arnulfo Mendoza; Chand Khanna; Mark J Hoenerhoff; Jeffrey E Green Journal: J Clin Invest Date: 2013-12-09 Impact factor: 14.808
Authors: Da Zhi Liu; Ben Waldau; Bradley P Ander; Xinhua Zhan; Boryana Stamova; Glen C Jickling; Bruce G Lyeth; Frank R Sharp Journal: J Cereb Blood Flow Metab Date: 2016-01-01 Impact factor: 6.200